How Theranostics Differs From the Current Prostate Cancer Treatment Options

While the current field of prostate cancer research is experiencing an era of “warp speed developments”, perhaps the most exciting option on the horizon is theranostics, according to Dr. Phillip J. Koo.
In a recent interview with CURE, Koo, the chief of diagnostic imaging at Banner MD Anderson Cancer Center in Phoenix, explained how theranostics, or the method of using one radioactive drug to identify cancer and a second radioactive drug to treat that cancer, is fundamentally different from the currently available therapies in prostate cancer.
View more at curetoday.com/
CURE: Combining science and humanity to make cancer understandable.